Page 5,984«..1020..5,9835,9845,9855,986..5,9906,000..»

SA STGEC ~ SIA12: Aging Eyes-OT (2012) – Video

Posted: Published on December 13th, 2012

SA STGEC ~ SIA12: Aging Eyes-OT (2012) San Antonio/June, 2012 - Summer Institute in Aging: Ms. Melva-Perez Andrews on "The Role of Occupational Therapy in Low Vision Rehabilitation". For more information on securing geriatric education videos on topics ranging from dementia and pharmacy to caregiving and diabetes, simply surf to http://WWW.STGEC.NET (The views, opinions, or conclusions expressed in this video are not given nor endorsed by any city, county, state or federal institution or authority--profit or non-profit.)From:GECGroupViews:2 1ratingsTime:01:06:47More inEducation Read more from the original source: SA STGEC ~ SIA12: Aging Eyes-OT (2012) - Video … Continue reading →

Posted in Pharmacy | Comments Off on SA STGEC ~ SIA12: Aging Eyes-OT (2012) – Video

SA STGEC ~ SIA12: Aging Eyes (2012) – Video

Posted: Published on December 13th, 2012

SA STGEC ~ SIA12: Aging Eyes (2012) San Antonio/June, 2012 - Summer Institute in Aging: Dr. Sandra Fox on on "Normal Vision Changes, Ocular Disease and Vision Impairment in the Aging Population". For more information on securing geriatric education videos on topics ranging from dementia and pharmacy to caregiving and diabetes, simply surf to http://WWW.STGEC.NET (The views, opinions, or conclusions expressed in this video are not given nor endorsed by any city, county, state or federal institution or authority--profit or non-profit.)From:GECGroupViews:1 1ratingsTime:59:24More inEducation Read more from the original source: SA STGEC ~ SIA12: Aging Eyes (2012) - Video … Continue reading →

Posted in Pharmacy | Comments Off on SA STGEC ~ SIA12: Aging Eyes (2012) – Video

SA STGEC ~ SIA12: Alcohol in Aging (2012) – Video

Posted: Published on December 13th, 2012

SA STGEC ~ SIA12: Alcohol in Aging (2012) San Antonio/June, 2012 - Summer Institute in Aging: Dr. William Beer on "Evidenced-based Health Promotion: Drug Alcohol Abuse in Aging". For more information on securing geriatric education videos on topics ranging from dementia and pharmacy to caregiving and diabetes, simply surf to http://WWW.STGEC.NET (The views, opinions, or conclusions expressed in this video are not given nor endorsed by any city, county, state or federal institution or authority--profit or non-profit.)From:GECGroupViews:1 1ratingsTime:01:00:07More inEducation Originally posted here: SA STGEC ~ SIA12: Alcohol in Aging (2012) - Video … Continue reading →

Posted in Pharmacy | Comments Off on SA STGEC ~ SIA12: Alcohol in Aging (2012) – Video

SA STGEC ~ SIA12: Drug Reactions (2012) – Video

Posted: Published on December 13th, 2012

SA STGEC ~ SIA12: Drug Reactions (2012) San Antonio/June, 2012 - Summer Institute in Aging: Dr. Heather Payton on "Adverse Drug Reactions in Aging". For more information on securing geriatric education videos on topics ranging from dementia and pharmacy to caregiving and diabetes, simply surf to http://WWW.STGEC.NET (The views, opinions, or conclusions expressed in this video are not given nor endorsed by any city, county, state or federal institution or authority--profit or non-profit.)From:GECGroupViews:1 1ratingsTime:38:16More inEducation See the rest here: SA STGEC ~ SIA12: Drug Reactions (2012) - Video … Continue reading →

Posted in Pharmacy | Comments Off on SA STGEC ~ SIA12: Drug Reactions (2012) – Video

SA STGEC ~ SIA12: Pharmacy Pearls (2012) – Video

Posted: Published on December 13th, 2012

SA STGEC ~ SIA12: Pharmacy Pearls (2012) San Antonio/June, 2012 - Summer Institute in Aging: Dr. Sharon Jung-Tschirhart on "Clinical Pharmacy Pearls in Aging". For more information on securing geriatric education videos on topics ranging from dementia and pharmacy to caregiving and diabetes, simply surf to http://WWW.STGEC.NET (The views, opinions, or conclusions expressed in this video are not given nor endorsed by any city, county, state or federal institution or authority--profit or non-profit.)From:GECGroupViews:1 1ratingsTime:01:01:26More inEducation Excerpt from: SA STGEC ~ SIA12: Pharmacy Pearls (2012) - Video … Continue reading →

Posted in Pharmacy | Comments Off on SA STGEC ~ SIA12: Pharmacy Pearls (2012) – Video

SA STGEC ~ SIA12: Aging Ear (2012) – Video

Posted: Published on December 13th, 2012

SA STGEC ~ SIA12: Aging Ear (2012) San Antonio/June, 2012 - Summer Institute in Aging: Dr. Robert Novak on "Assessment Treatment of hearing Loss in the Elderly". For more information on securing geriatric education videos on topics ranging from dementia and pharmacy to caregiving and diabetes, simply surf to http://WWW.STGEC.NET (The views, opinions, or conclusions expressed in this video are not given nor endorsed by any city, county, state or federal institution or authority--profit or non-profit.)From:GECGroupViews:1 1ratingsTime:56:01More inEducation See original here: SA STGEC ~ SIA12: Aging Ear (2012) - Video … Continue reading →

Posted in Pharmacy | Comments Off on SA STGEC ~ SIA12: Aging Ear (2012) – Video

VIHA Pharmacy Education Modules – Video

Posted: Published on December 13th, 2012

VIHA Pharmacy Education Modules Pharmacy Education ModulesFrom:Sean SpinaViews:0 0ratingsTime:00:55More inEducation Continue reading here: VIHA Pharmacy Education Modules - Video … Continue reading →

Posted in Pharmacy | Comments Off on VIHA Pharmacy Education Modules – Video

Fred Hutchinson Cancer Research Center Partners With GlaxoSmithKline to Develop Muscular Dystrophy Therapeutics

Posted: Published on December 12th, 2012

SEATTLE, Dec. 10, 2012 /PRNewswire/ --Fred Hutchinson Cancer Research Center and GlaxoSmithKline PLC (GSK) today announced a partnership to develop therapeutics to treat an inherited form of muscular dystrophy. The goal of the new agreement is to develop a small-molecule-based medicine to potentially reverse facioscapulohumeral muscular dystrophy, or FSHD, by inhibiting the activity of a protein that is incorrectly expressed by the DUX4 gene in people with the disease. The protein activity is what damages muscle cells and leads to progressive muscle weakness and atrophy in FSHD patients. The genetic and disease mechanisms of FSHD were discovered by an international team of scientists led by Stephen Tapscott, M.D., Ph.D., a member of the Fred Hutch Human Biology Division, in a series of studies published between 2010 and early 2012. Tapscott will lead the Fred Hutch work in the GSK collaboration. The team's discoveries also have implications for developing cancer immunotherapies because researchers also discovered that DUX4 regulates cancer/testis antigens. Cancer/testis antigens are encoded by genes that are normally expressed only in the human germ line but are also abnormally expressed in various tumor types, including melanoma and carcinomas of the bladder, lung and liver. This knowledge will give researchers a … Continue reading →

Posted in Muscular Dystrophy Treatment | Comments Off on Fred Hutchinson Cancer Research Center Partners With GlaxoSmithKline to Develop Muscular Dystrophy Therapeutics

The Epilepsy Drug Market Will Increase $800 Million by 2016, Primarily Due to Uptake of Premium-Priced Third …

Posted: Published on December 12th, 2012

BURLINGTON, Mass.--(BUSINESS WIRE)-- Decision Resources, one of the worlds leading research and advisory firms for pharmaceutical and healthcare issues, finds that the epilepsy market will increase from $2.9 billion in 2011 to nearly $3.7 billion in 2016. The expanding number and growing uptake of third-generation antiepileptic drugs (AEDs), led by lacosamide (UCBs Vimpat) and including other agents such as perampanel (Eisais Fycompa), eslicarbazepine acetate (Sunovion/Bial/Eisais Zebinix/Stedesa*) and ezogabine/retigabine (GlaxoSmithKline/Valeants Potiga/Trobalt), will be a major contributor to such growth. The Pharmacor advisory service entitled Epilepsy also finds that the second-generation AED drug class will maintain its major-market sales-leader position through 2021. Second-generation agents, such as levetiracetam (UCB/Otsuka Pharmaceuticals Keppra/E Keppra, generics; UCBs Keppra XR, generics) and lamotrigine (GlaxoSmithKline/Justes Lamictal, other brands, generics; GlaxoSmithKlines Lamictal XR), continue to displace older, first-generation AEDs across the major-pharmaceutical markets. Notably, agents in this drug class will experience robust uptake in Japan, as many of these drugs have recently launched there, and the U.S. market will see the launch and uptake of extended-release formulations of select members of the drug class, such as SPN-804 (Supernuss Oxtellar XR). At the same time, the use of third-generation AEDs will not supersede that of second-generation drugs, as the former … Continue reading →

Comments Off on The Epilepsy Drug Market Will Increase $800 Million by 2016, Primarily Due to Uptake of Premium-Priced Third …

SynapDx Corporation Secures $6 Million to Advance Efforts in Early Detection of Autism

Posted: Published on December 12th, 2012

SOUTHBOROUGH, Mass.--(BUSINESS WIRE)-- While children can demonstrate symptoms of autism spectrum disorders (ASDs) as early as 19 months, the average age of ASD diagnosis is 4.5 years old. Driven by increasing research pointing to the impact of early ASD detection and treatment, SynapDx Corporation has received $6 million in financing from North Bridge Venture Partners and General Catalyst Partners to support further development of its breakthrough blood-based ASD diagnostic test, designed to identify children with ASD by age 36 months. SynapDx has proven that it has the right combination of scientific, clinical and entrepreneurial expertise to develop tests that will offer parents and pediatricians a better, faster way to identify these disorders, said Bill Geary, Partner, North Bridge Venture Partners. The companys next phase of clinical development will be critical to thousands of children and their families. SynapDxs blood-test approach measures differences in RNA gene expression to distinguish between children with a higher risk for ASDs from those without. The test could hasten the diagnostic process and help children at risk for ASDs secure access to the right evaluations and treatment as early as possible. In its first phase, SynapDx obtained an exclusive license to recently-published discoveries from Boston Childrens … Continue reading →

Comments Off on SynapDx Corporation Secures $6 Million to Advance Efforts in Early Detection of Autism

Page 5,984«..1020..5,9835,9845,9855,986..5,9906,000..»